Phase I – Other

1,064 trials 249 recruiting

Filter these 1,064 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ… Ended

2022-500116-18-00 Advanced Solid Tumors 2023-01-09
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condi… Ended

2022-502200-67-00 Non-small Cell Lung Cancer 2022-12-27
Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia. Ended

2024-517377-24-00 Subjects with AML ( Acute myeloid leukaemia) or MDS (My 2022-12-20
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytis… Ended

2022-500921-34-00 Nicotine addiction 2022-12-13
A study in healthy women to test whether BI 425809 influences the amount of a contraceptive in the blood Ended

2022-500050-42-00 Healthy 2022-11-24
A study investigating the pain-relieving effects of a new drug in healthy adults Ended

2022-501804-80-00 Acute and chronic neuropathic pain secondary to diabeti 2022-11-17
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment … Ended

2022-500774-34-00 Urticaria 2022-11-08
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment co… Ended

2022-500775-31-00 Allergic rhinitis 2022-11-08
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Partici… Ended

2023-509188-26-00 Systemic Lupus Erythematosus (SLE) 2022-10-27
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended

2023-508404-37-00 Non-muscle Invasive Bladder Cancer 2022-10-26
A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the blo… Ended

2024-513656-15-00 Alzheimer's Disease (Healthy Participants) 2022-10-17
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisin… Ended

2022-500954-40-00 Nicotine addiction 2022-10-17
Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended

2024-515196-35-00 Platinum-Resistant Ovarian Cance 2022-09-29
Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended

2022-500287-35-00 Metastatic or Locally Advanced Unresectable Solid Tumor 2022-09-21
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Pa… Ended

2023-504412-14-00 Early Idiopathic Parkinson’s Disease (PD) 2022-09-01
A study to learn how the study drug elinzanetant (BAY 3427080) affects the way the drug dabigatran moves into, through and out of the body i… Ended

2022-500201-41-00 Healthy volunteers (Vasomotor Symptoms as a sex hormone 2022-08-02
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone … Ended

2024-516661-37-00 Metastatic Prostate Cancer 2022-07-27
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Ended

2024-516743-34-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 2022-07-25
Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type gl… Ended

2024-514424-16-00 MGMT-Methylated, IDH wild-type glioblastoma 2022-07-04
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero… Ended

2022-502981-26-00 Systemic Sclerosis 2022-06-27
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C… Ended

2024-514532-24-00 Solid cancer tumors 2022-06-23
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination… Ended

2024-511352-41-00 advanced solid tumors 2022-06-13
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo… Ended

2024-510644-31-00 Relapsed/Refractory Multiple Myeloma 2022-06-10
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and p… Ended

2024-516692-32-00 Refractory metastatic Her2 positive breast cancer 2022-05-26